

Section: 20. Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

		EMLc	Codes ATC: N07AA01
Indication	Myasthenia gravis	Code ICD11: 8C70.Z	
INN	Neostigmine bromide		
Type de médicament	Chemical agent		
Type de liste	Liste de base (EML) (EMLc)		
Formulations	Oral > Solid: 15 mg (neostigmine bromide) Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate) ; 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)		
Historique des statuts LME	Ajouté pour la première fois en 1977 (TRS 615) Modifié en 1979 (TRS 641) Modifié en 1989 (TRS 796) Modifié en 2003 (TRS 920) Modifié en 2007 (TRS 950)		
Sexe	Tous		
Âge	Aussi recommandé pour les enfants		
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique		
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets. 		
Wikipédia	Neostigmine 		
DrugBank	Neostigmine 		

Résumé des preuves et recommandation du comité d'experts

The EMLc Subcommittee noted that neostigmine metilsulfate injection was the preferred agent for the reversal of non-depolarising muscle block and endorsed neostigmine injection for inclusion in the EMLc. While neostigmine bromide tablets are licensed for use in infants and children for the treatment of myasthenia gravis, the Subcommittee noted that pyridostigmine has fewer cholinergic adverse effects and is now regarded as the first-line drug treatment for myasthenia gravis. The Subcommittee endorsed neostigmine (injection and tablet forms) and pyridostigmine (injection and tablet forms) for inclusion in the EMLc, with the latter retained in the Complementary List.

